NOL and Void

05 April 2010 Publication
Authors: Gardner F. Davis Danielle R. Whitley

The Deal

Foley Partner Gardner Davis and Senior Counsel Danielle Whitley authored an article titled “NOL and void” in the April 5, 2010 issue of The Deal. The authors discuss a Delaware Court of Chancery decision that upheld Selectica Inc.'s selection of a shareholder rights plan, or poison pill, as a tool to protect its net operating loss carry forwards (NOLs), remarking that it is the first time that a Delaware court has reviewed a board’s decision to adopt a poison pill intended to guard NOLs. They add that the decision should not be interpreted as support for the suggestion that a board can safely adopt a poison pill in every circumstance, noting the court’s acknowledgment that shareholder rights plans must be subject to careful review.

Related Services


Foley Weekly Automotive Report
03 August 2021
Dashboard Insights
Podcast Episode 57: Kristel Schorr, Partner
03 August 2021
Foley Career Perspectives
New Facebook Policy Requires Certification and Pre-Approval for Telemedicine Company Advertisements
03 August 2021
Health Care Law Today
Act Now: Employer Obligations Under New York HERO Act
02 August 2021
Labor & Employment Law Perspectives
30th Annual Law of Product Distribution & Franchise Seminar
29 September | 7 & 20 October 2021
Milwaukee | Chicago | Dallas
7th National Telehealth Summit
4-5 October 2021
Miami Beach, FL
AHLA Fraud & Compliance Forum
21-22 September 2021
Baltimore, MD
2nd Clinical Trial Agreements Forum
16-17 September 2021
Online Livestream